Procurement
Expert Panel
Create New Account
Login
Ken Research Logo
Report store
Insights
Survey
Consulting
Book discovery call
Ken Research Logo

The US Biotechnology Market Outlook to 2016

Future Growth Led by Surging Biotech Application in Agriculture, Health and Industrial Sector

Region:North America

Product Code:KR04

Download Sample Report
Published On

November 2012

Total pages

111

About the Report

 The report titled 'The US Biotechnology Market Outlook to 2016 - Future Growth Led by Surging Biotech Application in Agriculture, Health and Industrial Sector' provides a detailed description of the biotechnology market scenario in the US and a comprehensive analysis of the various qualitative and quantitative factors that are influencing the market. The report depicts the size of the biotech industry, biopharmaceuticals, biopesticides and bioseeds, biofuel and bioenzymes segments in the US, a competitive landscape and profiles of key players in these segments and the recent trends and developments in the biotechnology market in the US. The report also covers future outlook and projections for the different segments as well as the overall US biotechnology market on the basis of several industry factors that will shape the growth of this market in next five years.
 
The biotechnology market in the US has witnessed a rapid expansion in recent years driven by increased biotechnology applications in various sectors such as agriculture, food, health, medical and environmental sciences. The application in the human health dominates the US biotechnology market followed by agricultural and industrial applications. The biotechnology industry in the US is comprised of large multinational corporations, small entrepreneurial firms, various public and private research entities, dedicated biotechnology investment companies, bioinformatics companies and academia. The US biotechnology industry revenues have increased from USD 73 billion in 2006 to USD ~ billion in 2011 by growing at a CAGR of ~% during 2006-2011. The falling supply and production of oil, gas and coal and wide attention to the environmental impacts has also increased the demand for biotechnology engineered energy sources such as biofuels.
 
The US biotechnology market can be classified into three segments- Bio-Pharma, Industrial biotechnology and Agricultural biotechnology. The bio-pharma represents the largest segment in the US biotechnology market. This is followed by industrial biotechnology which is the second largest contributor in the US biotechnology market. Biologic drugs are gradually increasing their share over the period. Biological drugs are generally more expensive than the conventional drugs thus acting as a key revenue earners for producers. The total US biologic drugs market grew from USD ~ billion in 2006 to USD ~ billion in 2011 at a 5 year CAGR of 7.7%. Biologic drugs has high potential for future growth because of better long term outcomes with fewer costly side effects. Bristol-Myers Squibb is the largest company in the US in terms of biopharmaceutical drugs sales. The company held a market share of ~% and recorded sales of USD ~ billion. The company focuses on developing drugs in the oncology therapeutic class.
 
The agricultural biotechnology in the US is widely popular among farmers owing to the benefits of tools like genetic engineering that has made crop production cheaper and more manageable. The use of biotech crops that are unaffected by plant diseases and insect pests also have reduced the use of synthetic pesticides. The US agricultural biotechnology market has grown at a CAGR of ~% during 2006-2011 to USD ~ million in 2011.
 
The biotech crops accounts for majority of the US agricultural biotechnology market while the bio-pesticides contribute very less as compared to biotech crops. The contribution of biotech crops in the US agricultural biotechnology market have increased from ~% to ~% over the five year duration of 2006-2011 while on the other hand the contribution of bio-pesticides have declined from ~% to ~% during the same period.
 
In 2011, the US accounted for almost 3/4th of the total biotech crop production across the world with total hectarage of ~ million hectares dedicated to the production of biotech crops. The bio-pesticides market in the US has recorded a CAGR of ~% during 2006-2011. After 2009, the market gained momentum again and was recorded at USD ~ million in 2011. This reflects an increase in the adoption of bio-pesticides by the US farmers as a replacement to the toxic chemical pesticides. The various segments for the consumption of bio-pesticides in the US market are organic agricultural industry, vegetable farming, orchard crops and berries, federal and municipal programs for the management and treatment of forests, water resources and green belts in urban areas.
 
The development and adoption of industrial biotechnology has witnessed an unprecedented growth in the US in last five years. The substitution of conventional liquid fuels with liquid biofuels is widely considered as an important step towards energy security by reducing crude petroleum imports. The biofuel industry in the US grew at a CAGR of ~% from the period 2006-2011. The market in the US has increased by ~% in 2011 to USD ~ million due to rise in the government mandate blending rate targets. In the US the Environmental Protection Agency (EPA) has mandated a minimum level of biofuel consumption between 2006 and 2022. The market is expected to experience a CAGR of 12.1% from 2012-2016 following which the industry is expected to record revenue of USD ~ million in 2016. The US market for industrial enzymes can be categorized into ' Detergent Enzymes, Technical Enzymes, Food & beverage enzymes and Animal Feed enzymes. The US market for bio-enzymes was registered revenues of USD ~ million in 2011 while in 2006
the size of the market was USD ~ million. This accounts for a CAGR of ~% during 2006-2011.
 
The various trends such as growing old population, increasing emphasis on the sustainable renewable energy alternatives to reduce the dependency on the import of the oil, decreasing arable land and the increasing demand for food and the ability of biotech products and services to meet all these demands are expected to drive the US biotechnology market positively in next five years. Due to these factors the US biotechnology market is expected to grow at a CAGR of 10.2% during 2012-2016 to reach USD ~ million in 2016 from USD ~ million in 2012.
 
Key Topics Covered in the Report:
  • The market size of the US Biotechnology Market by revenue for the period 2006-2011.
  • Market segmentation of the US biotechnology market on the basis of bio-pharmaceuticals, agricultural biotechnology and industrial, 2006-2011.
  • Market size, introduction and future outlook/projections of the US bio-pharmaceutical market.
  • Company Profiles of major companies in the US bio-phrmaceuticals market.
  • Market size, introduction and future outlook/projections of the US agriculture biotechnology market.
  • Market segmentation of the US agricultural biotechnology market on the basis of biotech crops and bio-pesticides.
  • Market size, introduction and future outlook/projections of the biotech crops and bio-pesticides market of the US.
  • Trends and Development of the US agricultural biotechnology market.
  • Company Profiles of major companies in the US agricultural biotechnology market.
  • Market segmentation of the US industrial biotechnology market on the basis of biofuels and bio-enzymes.
  • Market size, introduction and future outlook/projections of the biofuels and bio-enzymes market of the US.
  • Trends and Development of the US industrial biotechnology market.
  • Company Profiles of major companies in the US bio-enzymes market.
  • Future outlook and projections of the US biotechnology market, 2012-2016.
 

Products

biotech industry, biopharmaceuticals, biopesticides and bioseeds, biofuel and bioenzymes, Biologic

Companies

Pfizer, Merck & Co, Novartis, AstraZeneca, GlaxoSmithKline, Monsanto, Syngenta, BASF, Dow AgroSciences, Bayer AG, NOVOZYMES, GENENCOR

Table of Contents

1. The US Biotechnology Market Introduction

2. The US Biotechnology Market Size by Revenue, 2006-2011

3. The US Biotechnology Market Segmentation By Application, 2006-2011

3.1. The US Bio-Pharmaceutical/Biologics Market Size and Introduction, 2006-2011

3.1.1. Top Selling Biologic Drugs, 2010

3.1.2. The US Bio-Pharmaceuticals Market Trends And Developments

Bio-Pharmaceutical Companies Focus on Outsourcing as Short Term Strategy

High Approvals Increasing the Number of Bio-Pharmaceutical Products

3.1.3. Top US Biopharmaceutical Companies Market Share, 2011

3.1.4. Biologic Drugs Future Projections, 2012-2016

3.1.5. Major Bio-Pharmaceutical Company Profiles

3.1.5.1. Pfizer Inc

Company Overview

Business Strategies

Financial Performance

3.1.5.2. Merck & Co

Company Overview

Business Strategies

Financial Performance

3.1.5.3. Novartis

Company Overview

Business Strategies

Financial Performance

3.1.5.4. AstraZeneca

Company Overview

Business Strategies

Financial Performance

3.1.5.5. GlaxoSmithKline

Company Overvie

Business Strategies

Financial Performance

3.1.6. Macro Economic and Industry Indicators: Current and Projections

3.1.6.1. Population, 2005-2015

3.1.6.2. Inpatient Admissions & Outpatients Visits, 2005-2010

3.1.6.3. Number of People with Health Insurance, 2005-2010

3.1.6.4. Prescription Drug Price index, 2005-2015

3.1.6.5. Personal Disposable Income, 2005-2015

3.2. The US Agricultural Biotechnology Market Size and Introduction 2006-2011

3.2.1. The US Agricultural Biotechnology Market Segmentation, 2006-2011

3.2.2. The US Biotechnology Crop Market Size, 2006-2011

3.2.2.1. By Crop Area, 2006-2011

3.2.2.2. By Revenue, 2006-2011

3.2.3. The US Biotechnology Crop Market Future Outlook/Projections, 2012-2016

3.2.3.1. By Crop Area and Revenue, 2012-2016

3.2.4. The US Bio-Pesticides Market Size and Introduction, 2006-2011

3.2.5. The US Bio-Pesticides Market Future Outlook and Projections, 2012-2016

3.2.6. The US Agriculture Biotechnology Market Trends and Developments

Labeling of GM Food in The US Market

The US Supermarkets Selling Privately Labeled Organic Products

3.2.7. The US Agricultural Biotechnology Future Outlook and Projections 2012-2016

3.2.8. Company Profiles of Major Companies in the US Agricultural Biotechnology Market

3.3. The US Industrial Biotechnology Market Size and Introduction 2006-2011

3.3.1. The US Industrial Biotechnology Market Segmentation, 2006-2011

3.3.2. The US Biofuel Market Size by Revenue, 2006-2011

3.3.2.1. The US Biofuel Market Size by Production and Consumption, 2005-2011

3.3.2.2. The US Fuel Ethanol Import, 2005-2011

3.3.2.3. The US Bio Diesel Import and Export, 2005-2011

3.3.3. The US Biofuel Market Segmentation, 2006-2011

3.3.3.1. By Fuel Ethanol and Bio Diesel, 2006-2011

3.3.4. The US Biofuel Industry Future Projections, 2012-2016

3.3.4.1. By Value, 2012-2016

3.3.4.2. By Fuel Ethanol and Bio Diesel, 2012-2016

3.3.5. The US Bio-Enzymes Market Size by Revenue, 2006-2011

3.3.6. Company Profiles of Major Companies in US Bio-Enzymes Market, 2011

3.3.6.1. Novozymes

Company Overview

Business Strategies

Financial Performance

3.3.6.2. Genencor

Company Overview

Business Strategies

Financial Performance

3.3.7. The US Bio-Enzymes Market Future Outlook and Projections, 2012-2016

3.3.8. The US Industrial Biotechnology Market Trends And Developments

Increasing Government Blending Rate Targets

Shifting Focus Towards Advanced Biofuels

Growing Application of Industrial Enzymes For Biofuels

3.3.9. The US Industrial Biotechnology Future Outlook and Projections, 2012-2016

4. The US Biotechnology Market Future Outlook and Projections

4.1. Cause and Effect Relationship Between Industry Factors and The US Biotechnology Industry

5. Appendix

5.1. Market Definitions

5.2. Abbreviations

5.3. Research Methodology

Data Collection Methods

Approach

Variables (Dependent and Independent)

Multi Factor Based Sensitivity Model

Scenario Analysis

Final Conclusion

5.4. Disclaimer

Why Buy From Us?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

Our Reach Is Unmatched
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022